-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 26, local time, the US company Moderna formally sued Pfizer and its German partner BioNTech for infringing patent rights
Boehringer Ingelheim v.
Recently, the State Intellectual Property Office (SIPO) made a ruling in accordance with the Administrative Adjudication Measures for Major Patent Infringement Disputes that the patent of the innovative drug Ou Tangning ® (Ligliliptin Tablets) independently developed by Boehringer Ingelheim was infringed by Guangdong Dongguang Pharmaceutical Co.
In its ruling, the State Intellectual Property Office found that Dongguang had infringed a patent
It is worth noting that there are also patent protections that are done well, such as Humira, which can protect the exclusive market ownership of drugs all year round, leaving ample time
for the survival and development of pharmaceutical companies.
It is worth noting that there are also patent protections that are done well, such as Humira, which can protect the exclusive market ownership of drugs all year round, leaving ample time
for the survival and development of pharmaceutical companies.
Twilight "Medicine King" - Xiu Mei le Twilight "Medicine King" - Xiu Mei Le Twilight "Medicine King" - Xiu Mei Le
Abbvie's Xiu Mei Le sat on the throne of "Medicine King" for nearly 10 years, during which he encountered many challenges, in addition to other blockbuster products, there are continuous patent lawsuits
.
However, Xiu Meile was not sued because of patent infringement, but because the patent protection was too good and too "overbearing", resulting in the delay in listing
the imitation products.
In the refusal to fully count, at least 9 well-known pharmaceutical companies have filed lawsuits against AbbVie, including: Boehringer Ingelheim, Amgen, Samsung Bioepis/Merck, Mylan, Sanders, Fresenius Scarbie, Momenta, Pfizer, Coherus BioSciences
.
However, AbbVie won all the lawsuits, defended the glory of the "medicine king", and through settlement with these pharmaceutical companies, pushed the market time of their imitations to 2023, and won enough time
for AbbVie's pipeline iteration.
Boehringer Ingelheim v.
Boehringer Ingelheim v.
Recently, the State Intellectual Property Office (SIPO) made a ruling in accordance with the Administrative Adjudication Measures for Major Patent Infringement Disputes that the patent of the innovative drug Ou Tangning ® (Ligliliptin Tablets) independently developed by Boehringer Ingelheim was infringed by Guangdong Dongguang Pharmaceutical Co.
Recently, the State Intellectual Property Office (SIPO) made a ruling in accordance with the Administrative Adjudication Measures for Major Patent Infringement Disputes that the patent of the innovative drug Ou Tangning ® (Ligliliptin Tablets) independently developed by Boehringer Ingelheim was infringed by Guangdong Dongguang Pharmaceutical Co.
In its ruling, the State Intellectual Property Office found that Dongguang had infringed a patent
It is worth noting that there are also patent protections that are done well, such as Humira, which can protect the exclusive market ownership of drugs all year round, leaving ample time
for the survival and development of pharmaceutical companies.
It is worth noting that there are also patent protections that are done well, such as Humira, which can protect the exclusive market ownership of drugs all year round, leaving ample time
for the survival and development of pharmaceutical companies.
Twilight "Medicine King" - Xiu Mei le Twilight "Medicine King" - Xiu Mei Le Twilight "Medicine King" - Xiu Mei Le
Abbvie's Xiu Mei Le sat on the throne of "Medicine King" for nearly 10 years, during which he encountered many challenges, in addition to other blockbuster products, there are continuous patent lawsuits
.
However, Xiu Meile was not sued because of patent infringement, but because the patent protection was too good and too "overbearing", resulting in the delay in listing
the imitation products.
In the refusal to fully count, at least 9 well-known pharmaceutical companies have filed lawsuits against AbbVie, including: Boehringer Ingelheim, Amgen, Samsung Bioepis/Merck, Mylan, Sanders, Fresenius Scarbie, Momenta, Pfizer, Coherus BioSciences
.
However, AbbVie won all the lawsuits, defended the glory of the "medicine king", and through settlement with these pharmaceutical companies, pushed the market time of their imitations to 2023, and won enough time
for AbbVie's pipeline iteration.
